Latest News

Opsona Therapeutics Ltd. initiates a Phase II Study with OPN-305.

May 7th, 2013, Dublin, Ireland – Seroba Kernel's investee company, Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune and inflammatory diseases, today announced that it has initiated a phase II

Opsona Therapeutics Limited raises €33 million Series C equity financing to advance clinical development of its lead product OPN-305.

April 29th, 2013, Dublin, Ireland – Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $43 million) in a Series C financing. The participants in this Series C financing include existing investors, Novartis Venture

Apica Publishes in European Journal of Cardio-Thoracic Surgery.

5 April 2013 Dublin. Leading International clinicians have published the first paper on the clinical use of Seroba Kernel's investee company, Apica Cardiovascular's Access and Closure Device to deliver aortic valves through the apex of the heart. The paper, published in the Journal of Cardio-Thor